Artes Biotechnology  GmbH  
HomeAbout ARTESTechnologiesOfferProductsContact   
         
  Artes Biotechnology GmbH | Contract R&D Services

Artes Biotechnology GmbH | Contract R&D Services

Artes Biotechnology GmbH | Contract R&D Services
ARTES Biotechnology GmbH

Biotechnological Processes and Products for Today and Tomorrow
ARTES Biotechnology is a well established development partner for recombinant protein production. Several bio-pharmaceutical products and industrial enzymes have been successfully introduced worldwide in the market by our clients and licensees.

ARTES Biotechnology delivers safe, robust and cost efficient protein production based on microbial cell lines including yeast (Hansenula polymorpha, syn. Pichia angusta) and bacteria (E. coli).

Our unique virus like particle (VLP) platform is applied for development of safe and affordable vaccines.

ARTES´ proprietary technologies ensure freedom-to-operate and reliable, competitive production. WHO recommendation, international registration, FDA approval and GRAS certification are part of the track record achieved in our international collaborations.

Large scale manufacturing and full analytics in accordance with cGMP guidelines are warranted in collaboration with a network of industrial partners.

Today

A wide range of processes and products is available in our portfolio for immediate technology transfer.

Tomorrow

New cell lines and processes for your product of interest are developed specifically to meet your demands.

Artes Biotechnology GmbH | Contract R&D Services.

 
   news
15.05.2014 Strategic cooperation between ARTES & Sun Pharma

ARTES Biotechnology has entered into a strategic collaboration with a subsidiary of Sun Pharmaceutical Industries Ltd, an international specialty pharmaceutical company with a diversified product portfolio headquartered in Mumbai/India.

This step broadens ARTES' international client base and demonstrates its ability to attract blue chip pharmaceutical companies. Under the collaboration agreement, ARTES will be responsible to deliver top-class cell lines and production processes for several pharmaceutical targets.

As part of the strategic collaboration, Sun Pharma's subsidiary will also become a minority shareholder in ARTES.

 

 
Top of Page
  Copyright by Artes Biotechnology GmbH 2013